Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00535522 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00535522 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT00535522, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
Interventions
- DRUG TAK-285 Dose Escalation Cohorts
- DRUG TAK-285 Recommended Phase 2 Dosing Cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00535522
The ClinicalTrials.gov registry entry for NCT00535522 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-285 Dose Escalation Cohorts is the first listed.
NCT00535522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00535522 about?
NCT00535522 is a clinical study titled "A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer". The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
What is the current status of trial NCT00535522?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00535522?
The interventions under investigation include: TAK-285 Dose Escalation Cohorts (DRUG), TAK-285 Recommended Phase 2 Dosing Cohort (DRUG).
Who is sponsoring clinical trial NCT00535522?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.